The FDA is finally taking the first steps toward human trials of embryonic stem cell treatments. They held conferences Thursday and Friday to discuss creating a blueprint for the system. Apparently, their main concern is possible side-effects of the treatments, chiefly the long-term risk of tumors. Geron (http://www.geron.com/) was to submit the first proposal for a clinical trial.